CompletedPhase 2

Ovicidal Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation

Australia50 participantsStarted 2014-05

Plain-language summary

The purpose of the study was to evaluate ovicidal efficacy of a single application of abametapir lotion 0.74% w/w intended for the treatment of head lice.

Who can participate

Age range6 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Healthy male or female based on medical history
✓. Six months of age or older.
✓. Has an active head lice infestation with a minimum of 3 live head lice and at least 10 undamaged and unhatched head lice eggs in their hair.
✓. Agrees to an examination for head lice and compliance with the study procedures.
✓. All adult subjects must sign a written voluntary informed consent. For minors, the parent/ legal guardian agrees to the subject participating in the study as determined by the signing of an assent of informed consent.

Exclusion criteria

✕. Has scalp disease or a history of allergies or prior reactions to any head lice products.
✕. Has a condition that, in the opinion of the Investigator, may interfere with the study.
✕. Is receiving systemic or topical medication, which in the opinion of the Investigator, may compromise the integrity of the safety and/or efficacy assessments.
✕. Had treatment (over-the-counter (OTC) or home remedy medication) for head lice within 14 days prior to Day 0.
✕. Has received an investigational agent within 30 days prior to Day 0.

What they're measuring

Percentage of Hatched Eggs Pre Treatment Relative to Post Treatment

Timeframe: 14 days

Trial details

NCT IDNCT02097485

SponsorDr. Reddy's Laboratories Limited

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2014-09

Results submitted2020-09-01

View on ClinicalTrials.gov More Head Lice Infestation trials